Clee Medical Secures Seed Funding to Advance Real-Time Brain Imaging Technology

Clee Medical, a Geneva-based neurotechnology startup, has successfully closed its Seed financing round to accelerate the development of its ultra-high-resolution real-time imaging platform for brain surgery.

The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, Venture Kick, and continued support from Wyss Geneva.

At the core of the Geneva-based company’s innovation is Neuro Access, a minimally invasive platform combining ultra-high-resolution intraoperative Optical Coherence Tomography (OCT) with advanced navigation capabilities. The technology is designed to provide neurosurgeons with real-time visualization of delicate brain structures during stereotactic procedures — addressing a critical limitation in today’s operating rooms, where surgeons often rely on pre-operative imaging despite dynamic anatomical shifts during surgery.

“Neurosurgery still relies heavily on pre-operative imaging, while the reality in the operating room is dynamic and uncertain,” said Matthew Lapinski, Co-Founder and CEO of Clee Medical. “This Seed round allows us to bring a new level of real-time visibility into the brain, supporting safer procedures and expanding what minimally invasive neurosurgery can achieve.”

The funding will support clinical validation efforts and regulatory milestones, including the company’s first-in-human clinical study. Backed by an experienced team with a track record in market-leading neurosurgical platforms such as Medtronic’s StealthStation and Renishaw’s NeuroMate, Clee Medical aims to build a category-defining platform in neurotechnology.

With this milestone, Clee Medical transitions from preclinical development to clinical translation, strengthening Switzerland’s position as a hub for cutting-edge neurotechnology innovation.

➡️ Source: Press Release | 📸 ©Clee Medical, Clee Medical’s team